PFS 1144

Drug Profile

PFS 1144

Alternative Names: EO 122

Latest Information Update: 23 Dec 2002

Price : $50

At a glance

  • Originator Eisai Co Ltd; Purdue Frederick
  • Developer Purdue Frederick
  • Class Antiarrhythmics
  • Mechanism of Action Calcium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Arrhythmias

Most Recent Events

  • 23 Dec 2002 Discontinued - Phase-I for Arrhythmias in USA (unspecified route)
  • 23 Dec 2002 Discontinued - Phase-I for Arrhythmias in Japan (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top